LDLR and glioblastoma: In GBM, constitutive activation of EGFR (EGFRvIII mutant) leads to PI3K/AKT-dependent SREBF1 regulation with a consequent increase in lipogenesis and cholesterol uptake, which can be pharmacologically blocked by inhibiting the low-density lipoprotein receptor (LDLR) (Guo et al, 2011).